Optimi Health Requests Approval To Manufacture MDMA, Other Synthetic Psychedelics
20 juin 2022 09h00 HE
|
Optimi Health Corp.
VANCOUVER, British Columbia, June 20, 2022 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian company producing natural,...
Core One Labs’ Upgrades to OTCQB Venture Market
06 avr. 2022 08h30 HE
|
Core One Labs Inc.
VANCOUVER, British Columbia, April 06, 2022 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: “COOL”), (OTCQB: “CLABF”), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) a life sciences...
Core One Labs’ Files Milestone Patent for Protection of its Recombinant Production System for Optimized Biosynthetic N-methyltryptamine (NMT)
21 févr. 2022 16h00 HE
|
Core One Labs Inc.
VANCOUVER, British Columbia, Feb. 21, 2022 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (“Core One” or the “Company”) is pleased to announce that...
Core One Labs Expects Imminent Breakthrough to Produce NMT, Precursor to DMT
10 févr. 2022 03h00 HE
|
Core One Labs Inc.
VANCOUVER, British Columbia, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (“Core One” or the “Company”) is pleased to announce that,...
Core One Labs Announces Successful Proof of Concept and Files Patent for Protection of its Recombinant Production System for Optimized Biosynthesis of Psilocybin
21 janv. 2022 16h22 HE
|
Core One Labs Inc.
VANCOUVER, British Columbia, Jan. 21, 2022 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (“Core One” or the “Company”) is pleased to announce that...
Core One Labs Special Investor Webcast Rescheduled to Friday, January 21, 2022
18 janv. 2022 13h00 HE
|
Core One Labs Inc.
VANCOUVER, British Columbia, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABD), (Frankfurt: LD6, WKN: A3CSSU) (“Core One” or the “Company”) announces that the special...
Franciosi Consulting Reviewing the Use of Psilocybin for Treating Depression, Anxiety and Addiction
06 janv. 2022 14h00 HE
|
Franciosi Consulting Ltd.
VANCOUVER, British Columbia, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Lui Franciosi has been reviewing the science and history of psychedelic drugs for treating depression, anxiety and addiction....
Algernon Pharmaceuticals Completes Manufacturing of Psychedelic Drug DMT Appoints UK Stroke Experts for Phase 2
08 déc. 2021 07h04 HE
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPD) a clinical stage pharmaceutical...
Algernon Announces Positive Feedback on its Planned Phase 1/2a DMT Human Stroke Study
19 nov. 2021 07h00 HE
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) a clinical stage pharmaceutical...
Algernon Pharmaceuticals Establishes 6 hours as Optimum Treatment Period for DMT in Neuron Study
01 nov. 2021 07h00 HE
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...